Novoteris, LLC. Receives FDA and Health Canada Clearance to Start a Phase 2 Clinical Trial of its Thiolanox® Nitric Oxide for the Treatment of Cystic Fibrosis.

Garden Grove, CA—June 5, 2017:  Novoteris, LLC, a clinical stage medical device and pharmaceutical developer focused on innovative nitric oxide gas applications, announced today that both the US Food and Drug Administration and the Therapeutic Products Directorate of Health Canada have cleared its Phase 2 clinical trial application. Novoteris will now begin recruiting subjects into its Phase 2 trial that will be using inhaled nitric oxide for the treatment of Cystic Fibrosis (CF). This multi-center trial will randomize sixty subjects recruited from five cystic fibrosis research centers (Seattle, Los Angeles, Milwaukee, Charleston and Vancouver) to either Thiolanox® nitric oxide product…

Continue Reading Novoteris, LLC. Receives FDA and Health Canada Clearance to Start a Phase 2 Clinical Trial of its Thiolanox® Nitric Oxide for the Treatment of Cystic Fibrosis.